Vytorin Class Action

BREAKING NEWS (1/17/2008): A lawsuit has been filed by the law firm of Parker Waichman LLP to get a refund for those who use Vytorin.

Martindale-Hubbell Peer Review Rated For the Ethical Standards and Legal Ability.

Martindale-Hubbell Peer Review Rated For the Ethical Standards and Legal Ability.

The makers of Vytorin have been named as defendants in a lawsuit filed by a New York man who took the defective drug based on the belief that it offered more protection from clogged arteries, heart attacks and strokes than other, less expensive statin drugs. Sigmond Tomaszewski, who began taking Vytorin in January 2007, alleges that Merck and Schering-Plough knew in April 2006 that Vytorin was ineffective at reducing artery clogging plaque, heart attacks and strokes, but purposely kept that information

Read More

Vytorin Ineffective in Preventing Clogged Arteries

Vytorin, developed and marketed jointly by Merck and Schering-Plough, is a combination of cholesterol-lowering Zetia and the statin Zocor. Statins like Zocor reduce the amount of cholesterol produced by the liver, while Zetia lessens the amount of cholesterol in food that is absorbed in the intestines. High cholesterol levels put a person at risk of developing clogged arteries. It was thought that by using Vytorin

Read More

Controversy Surrounding the ENHANCE Study

The medical community, eager to know if Vytorin lived up to its promise, had anxiously awaited the results of ENHANCE. But doctors and patients were forced to wait longer than expected for the ENHANCE data. The ENHANCE results should have been released by March 2007, but that didn’t happen.   In November 2007, the doctor who supervised the ENHANCE trial told the New York Times that the drug’s’ makers, who controlled the study’s raw data, blocked its release. In December of that year, a congressional committee requested more information on the ENHA NCE study. Merck and Schering-Plough maintained that the ENHANCE results were delayed because of the complexity of the data. According to the New York Times, Merck and Schering-Plough also tried at one point to change the ENHANCE study’s endpoint. The endpoint is the main

Read More

Legal Help

Parker Waichman, LLP is currently evaluating Vytorin product liability lawsuits against Merck and Schering-Plough. If you or a loved one used Vytorin under the assumption that it would reduce the risk of clogged

Read More